Trial ID or NCT#

NCT03373435

Status

RECRUITING

Purpose

This clinical study will evaluate whether taking an investigational drug called exendin 9-39 is safe, well-tolerated, and helps to prevent low blood sugar in people who have had bariatric surgery and later develop a rare condition called postbariatric hypoglycemia (PBH).

Official Title

A Phase 2, Multicenter, Randomized, Single-Blind, Placebo-Controlled Cross-over Study to Assess the Efficacy and Safety of Exendin 9-39 in Patients With Postbariatric Hypoglycemia

Eligibility Criteria

Ages Eligible for Study: 18 Years to 65 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Marilyn Tan, MD
Endocrinologist
Clinical Assistant Professor, Medicine - Endocrinology, Gerontology, & Metabolism

Contact us to find out if this trial is right for you.

CONTACT

Aileen Muno
(650) 725-9890